Category: Washington Focus

Washington Focus

Washington Focus

Political Pressure on Federal Health Agencies Is Eroding Public Trust

Political Pressure on Federal Health Agencies Is Eroding Public Trust

Sept. 14, 2020 – As the COVID-19 pandemic persists and the race for a vaccine to prevent contracting the virus heats up, there is a great deal of misinformation circulating about treatments and the majority of Americans are concerned that political pressure from the Trump administration will lead the Food and Drug Administration to approve […]

Read more

Washington Focus

Movement in White House-Pharma Industry Standoff on Drug Pricing?

Movement in White House-Pharma Industry Standoff on Drug Pricing?

Aug. 31, 2020 – Following the Democratic and Republican convention attacks on big pharma and President Trump’s acceptance speech for his party’s nomination for re-election – in which he claimed to have already taken effective action to lower prescription drug prices through Executive Orders  – the Pharmaceutical Research and Manufacturers of America (PhRMA) is making […]

Read more

Washington Focus

Trump Executive Order Calling for U.S. Production of Drugs Raises Eyebrows, Questions

Trump Executive Order Calling for U.S. Production of Drugs Raises Eyebrows, Questions

Aug. 7, 2020 – The Executive Order signed Aug. 6 by President Donald J. Trump  to increase production of essential medical supplies in the United States is raising a lot of eyebrows in the biopharmaceutical industry, largely because pivoting to such a model will not be easy and may end up costing more, both in […]

Read more

Washington Focus

Trump’s Drug Pricing Executive Orders Unlikely to Have Immediate Effect

Trump’s Drug Pricing Executive Orders Unlikely to Have Immediate Effect

July 27, 2020 – The four Executive Orders signed by President Trump on Friday were designed to address drug pricing concerns, but their combined impact is modest and they are “unlikely to have any immediate effect,” according to Coalition for Healthcare Communication Executive Director Jon Bigelow. However, they do “give the president talking points for […]

Read more

Washington Focus

Change in Hospital COVID-19 Case Reporting Raises Fear of Politicization of Data

Change in Hospital COVID-19 Case Reporting Raises Fear of Politicization of Data

July 20, 2020 – The Trump administration instructed hospital systems and providers last week that they should no longer report data on COVID-19 cases, hospitalizations, deaths, positive test results, etc. to the Centers for Disease Control and Prevention’s (CDC’s) National Healthcare Safety Network site, and instead should send this information to a newly launched data […]

Read more

Washington Focus

Senate Confirms Hahn to Be Next FDA Commissioner

Senate Confirms Hahn to Be Next FDA Commissioner

Dec. 13, 2019 – In a vote of 72-18 the Senate yesterday confirmed Dr. Stephen Hahn to take the helm of the Food and Drug Administration even though it had been predicted that the vote to confirm Hahn as FDA Commissioner might be pushed to 2020 in light of competing priorities like the budget and […]

Read more

Washington Focus

Hahn Confirmation Hearing Reveals Little about FDA Commissioner Nominee

Hahn Confirmation Hearing Reveals Little about FDA Commissioner Nominee

Nov. 20, 2019 – In today’s Senate confirmation hearing for Dr. Stephen Hahn, President Donald Trump’s nominee for the Commissioner of Food and Drugs position, Senate Health, Education, Labor, and Pensions (HELP) Committee members questioned Hahn on such topics as opioids, generic drugs, updating the over-the-counter drug monograph, regulating cannabis-related products, and combatting shortages of […]

Read more

Regulatory/FDA

Dr. Stephen Hahn Nominated for FDA Commissioner Position

Dr. Stephen Hahn Nominated for FDA Commissioner Position

Nov. 1, 2019 – In a statement issued by the White House, President Donald J. Trump today nominated Stephen Hahn, M.D., to be Commissioner of the Food and Drug Administration (FDA). Hahn is a radiation oncologist, experienced clinical trial investigator, and coauthor of more than 200 papers. He previously served as Chair of Radiation Oncology […]

Read more

Regulatory/FDA

Gottlieb: Lack of Permanent FDA Commissioner Has an Impact

Gottlieb: Lack of Permanent FDA Commissioner Has an Impact

Oct. 14, 2019 — “I’d be lying if I said it didn’t have an impact.” That’s how former FDA Commissioner Scott Gottlieb responded when asked last week at the BioPharma Congress in Washington, D.C., whether it matters if the FDA is led by an acting or a permanent Commissioner, even as reports swirl in Washington that […]

Read more

CHC News

Keeping Up with Washington Policy Is Key to Successful Career, Rising Leaders Panelists Say

Keeping Up with Washington Policy Is Key to Successful Career, Rising Leaders Panelists Say

Sept. 2, 2019 – Although healthcare marketing communicators and publishers are busy professionals with a lot on their plates, staying on top of healthcare policy developments in Washington, D.C., can both enhance and further their careers, according to panelists speaking at the recent Coalition for Healthcare Communication Rising Leaders Conference on Healthcare Policy. “Every time […]

Read more